A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)

Trial Profile

A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Corifollitropin alfa (Primary) ; Follitropin beta
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms PURSUE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 23 Oct 2012 Primary endpoint 'Pregnancy-rate' has been met, according to a Merck & Co. media release.
    • 02 Jul 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov (Parent trial: NCT01144416).
    • 02 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT01144416).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top